Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-2)
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of Two Doses of R935788 in Rheumatoid Arthritis Patients Failing to Respond to Methotrexate
Sponsor: Rigel Pharmaceuticals
This PHASE2 trial investigates Rheumatoid Arthritis and is currently completed. Rigel Pharmaceuticals leads this study, which shows 9 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
May 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Rigel Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Austin, United States , Barranquilla, Colombia , Bialystok, Poland , Bogota, Colombia , Bogotá, Colombia , Brăila, Romania , Bucaramanga, Colombia , Bucharest, Romania , Bytom, Poland , Charleston, United States and 43 more locations